LBM-based approach using synchronous transformation with a time step of 0.43s, PNGM-based method using asynchronous transformation with a 5s time step, VGA using explicit scheme wi... حسب Mouad Klai (20818364)

الموضوعات:

Effective contact rate over time for the different modelling scenarios considered: fixed, continuously increasing, continuously decreasing and with a step-decrease. حسب Joshua Looker (21390948)

"…<p>Effective contact rate over time for the different modelling scenarios considered: fixed, continuously increasing, continuously decreasing and with a step-decrease.</p>…"

Comparison of diffusion simulations: implicit scheme of the GDE with a 30-second time step (blue line), implicit scheme of the PNGM with α = 0.6 and a 15-second time step (green li... حسب Mouad Klai (20818364)

الموضوعات:

Disturbance of coherent behaviour leads to a decrease in information transfer. حسب Hannah Zoller (19688084)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. حسب Ryan J. Treves (13527735)

ANN architecture. حسب Abdelfattah Dani (22226715)

الموضوعات:

ANN architecture and configuration. حسب Abdelfattah Dani (22226715)

الموضوعات:

BST2 overexpression decreased RSV multiplication. حسب Katherine Marougka (13015146)

Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. حسب Cathryn S. D. Maienza (20629929)

Lens profiles as Ez (orange lines) force was increased and Az and Pz (green lines) forces were decreased. حسب Ronald A. Schachar (16674576)

Expression of lipid biosynthetic genes is decreased with polyamine depletion. حسب Yazmin E. Cruz-Pulido (20285238)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات: